Medical Pharmacology: Chapter 8: Antiarrhythmic Drugs -- Module 3: Class II Beta-Blockers in Arrhythmia Management

Chapter 8: Antiarrhythmic Drugs — Module 3: Class II Beta-Blockers in Arrhythmia Management
Tier: 3 — Clinical Vignettes (11 questions)

1. A 26-year-old man with CPVT (RyR2 mutation, out-of-hospital cardiac arrest at age 17) has been arrhythmia-free for 5 years on nadolol 80 mg daily. He develops new mild-to-moderate asthma (FEV1 72% predicted) and his pulmonologist requests switching to a beta1-selective agent. His most recent exercise stress test showed no arrhythmia at 85% maximum predicted heart rate. How should this conflict between arrhythmia management and pulmonary disease be resolved?

A) Switch to metoprolol succinate immediately. Asthma is an absolute contraindication to non-selective beta-blockers and patient safety requires the change regardless of arrhythmia risk.
B) Discontinue nadolol entirely and manage CPVT with flecainide monotherapy, which provides direct RyR2 stabilization without bronchospasm risk.
C) Maintain nadolol. Mild asthma is not an absolute contraindication in a patient with life-threatening arrhythmia history. Optimize inhaled therapy with beta2-agonist bronchodilators and inhaled corticosteroids. If severe bronchospasm supervenes despite inhaled therapy, consider ICD implantation before switching to a selective agent.
D) Switch to carvedilol. Its alpha1-blocking property reduces airway resistance by attenuating sympathetically driven bronchoconstriction.
E) Reduce nadolol to 20 mg daily and add metoprolol succinate 25 mg daily to compensate, providing partial non-selective coverage with reduced bronchospasm risk.

ANSWER: C

Rationale:

In CPVT, non-selective beta-blockade is a pharmacologic requirement, not a preference. This patient had an out-of-hospital cardiac arrest, establishing him as the highest-risk CPVT phenotype. His 5-year arrhythmia freedom on nadolol reflects treatment efficacy, not disease quiescence. Mild asthma is not an absolute contraindication to nadolol in a patient with life-threatening arrhythmia history. The governing pharmacologic principle is that the mechanism required for arrhythmia suppression (non-selective blockade of both beta1 and beta2 adrenergic receptors to prevent RyR2 phosphorylation by both receptor subtypes) takes precedence over the general preference for beta1-selective agents in airway disease. Inhaled beta2-agonist bronchodilators and inhaled corticosteroids can manage mild asthma while maintaining nadolol. If severe bronchospasm supervenes, ICD implantation as a safety net before any antiarrhythmic change is the appropriate escalation. Switching to metoprolol leaves beta2-mediated RyR2 activation intact, providing incomplete CPVT protection, and is not appropriate given this patient's cardiac arrest history.

2. A 71-year-old woman with persistent AF and HFrEF (EF 30%) is on metoprolol succinate 50 mg daily and amiodarone 200 mg daily for rhythm control. She presents with symptomatic bradycardia (heart rate 38 bpm) and a PR interval of 340 ms. Her AF has been in sinus rhythm for 8 months. Which pharmacologic interaction explains her presentation, and what is the immediate management priority?

A) Both metoprolol and amiodarone independently slow AV nodal conduction. Metoprolol does so through beta1 adrenergic blockade. Amiodarone does so through its Class II property (beta-blockade) in addition to its Class IV property (ICaL blockade in the AV node). Their combination produces additive AV nodal suppression that can cause symptomatic bradycardia and high-degree AV block. Immediate management requires reducing or withholding metoprolol rather than amiodarone, given amiodarone's weeks-long half-life makes it non-titratable in the acute setting.
B) Amiodarone inhibits CYP2D6 and causes metoprolol accumulation. The interaction is purely pharmacokinetic. Immediate management is dose reduction of metoprolol.
C) Both drugs prolong the QT interval through IKr blockade, and the combination causes bradycardia through QT-dependent rate slowing rather than direct AV nodal blockade.
D) Amiodarone competes with metoprolol for beta1 receptor binding, reducing metoprolol's effectiveness and causing a paradoxical receptor hypersensitivity that manifests as bradycardia.
E) The bradycardia is caused by amiodarone-induced hypothyroidism, not a direct drug interaction. Thyroid function should be checked and amiodarone discontinued.

ANSWER: A

Rationale:

This interaction involves two converging mechanisms. Metoprolol provides beta1 adrenergic blockade, reducing sympathetic drive to the AV node. Amiodarone independently slows AV nodal conduction through multiple mechanisms including its Class II property (intrinsic beta-blocking activity), its Class IV property (direct ICaL blockade in nodal tissue), and its Class I property (sodium channel blockade). The combination can produce clinically significant additive or synergistic AV nodal suppression. Additionally, amiodarone is a potent CYP2D6 inhibitor, raising metoprolol plasma concentrations by 2 to 3-fold, adding a pharmacokinetic component. Immediate management focuses on reducing or withholding metoprolol, since amiodarone's half-life of weeks to months makes acute dose reduction ineffective. If the patient requires rate or rhythm control, temporary pacing may be needed. Amiodarone-induced hypothyroidism can cause bradycardia but does not cause PR prolongation of this degree and is a subacute process.

3. A 68-year-old man with HFrEF (EF 25%), stage 3b CKD (creatinine clearance 34 mL/min), Child-Pugh class A cirrhosis, and persistent AF at 108 bpm requires initiation of guideline-directed beta-blocker therapy. He is currently euvolemic. Which agent and rationale best addresses his combined organ impairment?

A) Metoprolol succinate. Predominantly hepatic elimination via CYP2D6 avoids renal accumulation, and MERIT-HF provides the strongest mortality evidence.
B) Carvedilol. Alpha1 blockade reduces portal pressure in cirrhosis, and COPERNICUS established its benefit in severe HFrEF.
C) Nadolol. Its long half-life provides consistent plasma levels and non-selective blockade provides superior neurohormonal suppression in HFrEF.
D) Atenolol. Beta1 selectivity is ideal in HFrEF and its renal elimination at this CrCl does not require dose adjustment.
E) Bisoprolol. Its approximately 50% renal and 50% hepatic dual elimination pathway makes pharmacokinetics more predictable than predominantly hepatic agents in the presence of mild cirrhosis, while avoiding the excessive accumulation that purely renally eliminated agents experience at CrCl 34 mL/min. CIBIS-II demonstrated mortality benefit in symptomatic HFrEF.

ANSWER: E

Rationale:

This patient has three competing pharmacokinetic constraints: reduced renal clearance (CrCl 34 mL/min), mild hepatic impairment, and the need for a proven HFrEF agent. Bisoprolol's dual elimination route (approximately 50% renal, 50% hepatic) distributes the metabolic burden between both organs, making it less susceptible to accumulation when either organ is impaired individually. At CrCl 34 mL/min, bisoprolol requires dose adjustment but does not accumulate to the degree that purely renally eliminated agents (atenolol, nadolol) would. Compared to predominantly hepatically metabolized agents (metoprolol, carvedilol, propranolol), bisoprolol is less affected by mild cirrhosis. CIBIS-II established bisoprolol's mortality benefit in HFrEF. Atenolol at CrCl 34 mL/min requires dose reduction to 25 mg daily and lacks proven HFrEF mortality benefit. Carvedilol's predominantly hepatic metabolism makes it less predictable in cirrhosis. Nadolol has no proven HFrEF mortality data.

4. A 29-year-old woman with LQT1 (KCNQ1 mutation, one prior syncopal episode during swimming at age 14) is currently well-controlled on nadolol 80 mg daily. She presents at 8 weeks gestation asking whether her medication is safe during pregnancy and what arrhythmia risks pregnancy poses. What is the most accurate counseling?

A) Nadolol must be discontinued immediately. All beta-blockers are category X in pregnancy due to fetal bradycardia and growth restriction risk.
B) Beta-blockers including nadolol can be continued during pregnancy. LQT1 arrhythmia risk increases postpartum due to surges in adrenergic tone during labor and the immediate postpartum period, making beta-blocker continuation especially important. Nadolol crosses the placenta and can cause neonatal bradycardia and hypoglycemia, requiring neonatal monitoring after delivery. The benefit of preventing maternal arrhythmia outweighs fetal risk in this high-risk patient.
C) Switch to metoprolol succinate immediately. It is the safest beta-blocker in pregnancy because its beta1 selectivity reduces fetal beta2-mediated effects including uterine relaxation inhibition.
D) Beta-blockers are safe in pregnancy but should be discontinued 4 weeks before the expected delivery date to allow maternal beta-receptor upregulation and prevent neonatal withdrawal.
E) Nadolol is safe in pregnancy but LQT1 risk decreases during pregnancy due to estrogen-mediated IKs upregulation, so the dose can be reduced by half during the second and third trimesters.

ANSWER: B

Rationale:

Beta-blockers are the cornerstone of LQT1 management and should be continued through pregnancy. Discontinuation risks life-threatening arrhythmia in a patient who has already had a syncopal episode. The postpartum period is a time of particularly elevated arrhythmia risk in LQTS due to adrenergic surges during labor, delivery, and the immediate postpartum period. Nadolol crosses the placenta and can cause neonatal bradycardia, hypoglycemia, and respiratory depression. These neonatal effects are manageable with appropriate monitoring and do not outweigh the maternal benefit in a patient with symptomatic LQT1. The neonatal care team must be informed so they can monitor and treat as needed. Beta-blockers are not category X in pregnancy. Abrupt discontinuation before delivery risks maternal arrhythmia and withdrawal effects. Estrogen does not reliably upregulate IKs to a clinically significant degree, and dose reduction based on this rationale is unsupported.

5. A 34-year-old man with known cocaine use disorder presents with chest pain, BP 204/118 mmHg, heart rate 148 bpm, and AF on ECG. Troponin is mildly elevated. The emergency physician considers IV metoprolol for rate control and blood pressure management. A cardiology fellow argues that metoprolol is safe because the patient's tachycardia is the primary driver of his demand ischemia. Who is correct and what is the appropriate pharmacologic approach?

A) The emergency physician is correct. Beta1-selective agents are safe in cocaine toxicity because they do not block beta2 receptors and therefore do not cause unopposed alpha stimulation.
B) Both are partially correct. Metoprolol is safe for rate control but should be combined with nitroglycerin for blood pressure management to avoid the unopposed alpha effect on coronary vasculature.
C) The cardiology fellow is incorrect. Rate control takes priority over the theoretical unopposed alpha concern in a patient with demand ischemia and elevated troponin.
D) The cardiology fellow is correct. Beta-blockade in cocaine toxicity removes beta2-mediated vasodilation while leaving alpha1-mediated coronary vasoconstriction unopposed, paradoxically worsening ischemia and hypertension regardless of selectivity. The correct approach is benzodiazepines as first-line therapy, with phentolamine added for persistent hypertension, and rate control achieved through alpha-blockade and sedation rather than beta-blockade.
E) The cardiology fellow is correct regarding beta-blockers, but calcium channel blockers such as diltiazem are also contraindicated in cocaine toxicity due to additive coronary vasospasm.

ANSWER: D

Rationale:

The contraindication to beta-blockers in cocaine toxicity is absolute and applies to all beta-blockers including beta1-selective agents. Cocaine simultaneously activates both alpha and beta adrenergic receptors through norepinephrine reuptake inhibition. Beta2 activation in peripheral vasculature provides a counterbalancing vasodilatory effect against alpha1-mediated coronary and peripheral vasoconstriction. Administering a beta-blocker eliminates this beta2 counterbalance while leaving alpha1 vasoconstriction unopposed, paradoxically worsening hypertension and coronary vasospasm, the primary mechanism of cocaine-related myocardial infarction. The cardiology fellow's demand ischemia argument does not override this pharmacologic principle. Appropriate management is benzodiazepines for central sympathetic suppression (the primary intervention), phentolamine for alpha-blockade if hypertension persists, and nitroglycerin for vasodilation. Rate in cocaine-associated AF is typically driven by sympathetic excess and responds to benzodiazepines and sedation. Non-DHP CCBs such as diltiazem are not contraindicated in cocaine toxicity and can be used for rate control if benzodiazepines are insufficient.

6. A 59-year-old man with anterior MI 6 months ago (EF 42%), type 1 diabetes mellitus requiring insulin, and no prior history of HFrEF is being initiated on a beta-blocker for post-MI arrhythmia prophylaxis and secondary prevention. He reports difficulty recognizing hypoglycemia symptoms and has had two severe hypoglycemic episodes in the past year. Which beta-blocker selection and rationale is most appropriate?

A) Propranolol. Its non-selective beta-blockade provides the broadest post-MI mortality benefit and the hypoglycemia masking concern is overstated at standard doses.
B) Carvedilol. Its alpha1-blocking property improves insulin sensitivity through peripheral vasodilation, reducing the frequency of hypoglycemic episodes.
C) Atenolol or metoprolol succinate. Beta1-selective agents are preferred in insulin-dependent diabetes because non-selective agents block beta2-mediated compensatory tachycardia (the primary adrenergic warning sign of hypoglycemia) more completely than beta1-selective agents, increasing the risk of unrecognized severe hypoglycemia. Diaphoresis, a cholinergically mediated sign, is preserved by all beta-blockers and remains a useful warning.
D) Avoid all beta-blockers. Insulin-dependent diabetes with recurrent severe hypoglycemia is an absolute contraindication to beta-blocker therapy in post-MI patients.
E) Nadolol. Its long half-life provides more consistent beta-blockade, reducing the fluctuating adrenergic tone that precipitates hypoglycemia unawareness.

ANSWER: C

Rationale:

Beta-blockers mask some hypoglycemia warning symptoms in insulin-dependent diabetics, but the degree of masking depends on receptor selectivity. The primary adrenergic warning sign of hypoglycemia is tachycardia, mediated by beta1 and beta2 receptors. Non-selective agents (propranolol, nadolol, carvedilol) block both beta1 and beta2-mediated tachycardia more completely, substantially impairing this warning. Beta1-selective agents (atenolol, metoprolol, bisoprolol) preferentially block beta1, leaving some beta2-mediated compensatory tachycardia intact, providing a partial but meaningful early warning signal. Importantly, diaphoresis (sweating during hypoglycemia) is mediated by cholinergic pathways and is preserved regardless of beta-blocker selectivity, remaining a useful warning sign for all patients. Insulin-dependent diabetes is not an absolute contraindication to beta-blockers post-MI. The mortality benefit of post-MI beta-blockade substantially outweighs the hypoglycemia masking risk, particularly with beta1-selective agents and patient education about preserved warning signs.

7. A 41-year-old woman with a confirmed right adrenal pheochromocytoma is scheduled for laparoscopic adrenalectomy in 3 weeks. She has episodic hypertension (BP spikes to 220/130 mmHg), diaphoresis, and tachycardia at 118 bpm at baseline. Her surgeon asks whether propranolol should be started now for preoperative heart rate control. What is the correct preoperative pharmacologic sequence and why?

A) Phenoxybenzamine (an irreversible non-selective alpha adrenergic blocker) must be initiated first, titrated over 10 to 14 days to achieve blood pressure control and volume expansion. Only after adequate alpha-blockade is established should propranolol be added for heart rate control. Starting propranolol before alpha-blockade removes beta2-mediated vasodilation while leaving alpha1 vasoconstriction unopposed, risking a catastrophic hypertensive crisis.
B) Propranolol should be started immediately at low dose to control tachycardia. Alpha-blockers are added only if hypertension persists after adequate beta-blockade is achieved.
C) Both phenoxybenzamine and propranolol should be started simultaneously at low doses and titrated together over 2 weeks.
D) Beta-blockade is not needed preoperatively. Phenoxybenzamine alone is sufficient to control both hypertension and tachycardia in pheochromocytoma.
E) IV esmolol is the preferred preoperative agent because its short half-life allows intraoperative titration as catecholamine release varies during tumor manipulation.

ANSWER: A

Rationale:

Preoperative preparation for pheochromocytoma resection requires a mandatory sequence: alpha-blockade first, then beta-blockade. Phenoxybenzamine, an irreversible non-selective alpha adrenergic blocker, is the preferred initial agent. It is titrated over 10 to 14 days to achieve blood pressure below 130/80 mmHg and to restore intravascular volume depleted by chronic vasoconstriction. Alpha-blockade also reduces the magnitude of intraoperative hypertensive crises during tumor manipulation. Only after adequate alpha-blockade is established is propranolol added to control reflex tachycardia. The sequence is absolute: propranolol before alpha-blockade eliminates beta2-mediated vasodilation (which partially counterbalances alpha1 vasoconstriction) while leaving alpha1 unopposed, potentially causing a severe hypertensive crisis identical in mechanism to cocaine toxicity and beta-blocker administration in pheochromocytoma emergencies. Selective alpha1-blockers (prazosin, doxazosin) are used as alternatives to phenoxybenzamine at some centers. IV esmolol is useful for intraoperative catecholamine spikes during tumor manipulation but does not replace oral preoperative preparation.

8. A 62-year-old man with a Stanford type B aortic dissection (BP 196/108 mmHg, heart rate 114 bpm) has a documented history of mild intermittent asthma managed with an as-needed albuterol inhaler. The attending physician is reluctant to use IV esmolol due to the asthma history and instead orders IV nicardipine (a dihydropyridine calcium channel blocker) for blood pressure and heart rate control. Is this approach correct?

A) Yes. IV nicardipine is the preferred agent in aortic dissection with asthma because it reduces blood pressure without beta2 blockade.
B) Yes. Non-DHP CCBs such as diltiazem are preferred over beta-blockers in all aortic dissection patients with pulmonary comorbidities.
C) Partially correct. Nicardipine should be the primary agent but IV metoprolol should be added for heart rate control despite the asthma history.
D) No. IV esmolol is preferred and asthma history is irrelevant in aortic dissection because esmolol's Class IV calcium channel blocking property provides bronchodilation.
E) No. The primary goal in aortic dissection is reduction of dP/dt (rate of rise of aortic pressure), which requires heart rate reduction that vasodilators alone cannot reliably achieve. IV nicardipine is a dihydropyridine calcium channel blocker (DHP CCB) that causes reflex tachycardia, directly worsening dP/dt. IV esmolol is the preferred initial agent. Mild asthma is not an absolute contraindication to short-term beta1-selective IV esmolol in a life-threatening emergency. If bronchospasm occurs, esmolol's 9-minute half-life means effects resolve within 20 to 30 minutes.

ANSWER: E

Rationale:

Aortic dissection management prioritizes dP/dt reduction above all other hemodynamic goals. This requires heart rate reduction, which beta-blockers achieve directly. Vasodilators such as nicardipine reduce blood pressure but cause reflex tachycardia through baroreceptor activation, increasing dP/dt and worsening the dissection. DHP CCBs such as nicardipine are particularly problematic because their lack of intrinsic chronotropy means tachycardia is unattenuated. IV esmolol, despite this patient's asthma history, is the correct choice. Mild intermittent asthma is not an absolute contraindication to short-term beta1-selective IV beta-blockade in a life-threatening emergency. Esmolol's ultra-short half-life (9 minutes from red blood cell esterase hydrolysis) means that if bronchospasm develops, discontinuation restores normal physiology within 20 to 30 minutes. The reversibility of esmolol is precisely the property that makes it appropriate in patients with uncertain bronchospasm risk. If vasodilatory therapy is needed for BP targets after heart rate is controlled, IV sodium nitroprusside is added as a second agent, never as monotherapy.

9. A 17-year-old girl with CPVT (RyR2 mutation, aborted cardiac arrest at age 14) is on nadolol 80 mg daily plus flecainide 100 mg twice daily. Despite this combination she has had one episode of bidirectional VT during competitive soccer documented on her wearable cardiac monitor. Her parents ask whether the medications are working and whether anything more can be done. How should this be addressed?

A) The combination of nadolol plus flecainide represents maximum pharmacologic therapy for CPVT. No further intervention is available short of cardiac transplantation.
B) Despite partial pharmacologic suppression, ICD implantation is indicated in this patient given her aborted cardiac arrest history and breakthrough arrhythmia on optimal combination therapy. The nadolol plus flecainide regimen should continue alongside the ICD, as pharmacologic suppression reduces the frequency of ICD shocks and the risk of shock-induced psychological morbidity.
C) The flecainide dose should be increased to 200 mg twice daily. CPVT is dose-dependent and higher flecainide concentrations provide complete RyR2 stabilization.
D) Switch flecainide to amiodarone. Multi-channel blockade provides more comprehensive suppression than RyR2-targeted therapy alone in refractory CPVT.
E) Competitive athletics should be prohibited and the medications should be reassessed after a 6-month period of physical restriction. Exercise restriction is the primary therapy in refractory CPVT.

ANSWER: B

Rationale:

This patient has an aborted cardiac arrest history, the highest-risk CPVT phenotype, and continues to have breakthrough arrhythmia on combination nadolol plus flecainide therapy. ICD implantation is indicated. The ICD does not replace pharmacologic therapy. Beta-blockers and flecainide reduce the frequency of arrhythmia episodes and therefore the frequency of ICD therapies, which carry psychological burden and reduce quality of life, particularly in adolescents. The combination of optimal pharmacologic therapy plus ICD is the appropriate integrated strategy. Increasing flecainide beyond standard doses risks sodium channel toxicity including pro-arrhythmia. Amiodarone does not target the RyR2 mechanism and carries substantial long-term toxicity in a 17-year-old. Exercise restriction alone is insufficient in a patient with cardiac arrest history and breakthrough arrhythmia on dual therapy. Competitive athletics should be discussed with the patient and family in the context of shared decision-making, but restriction does not replace the ICD implantation indicated by her risk profile.

10. A 32-year-old man with known Wolff-Parkinson-White syndrome (WPW) presents with palpitations and a wide-complex irregular tachycardia at 210 bpm. The ECG shows pre-excitation with irregular RR intervals consistent with AF conducting through an accessory pathway (pre-excited AF). A nurse prepares IV metoprolol for rate control. Why is this contraindicated, and what is the correct management?

A) IV metoprolol is contraindicated because WPW involves a re-entrant circuit requiring Class Ic agents for termination rather than AV nodal blockers.
B) IV metoprolol is contraindicated because beta-blockers cause direct conduction enhancement through accessory pathways via sympathomimetic activity at the bypass tract.
C) IV metoprolol is safe in pre-excited AF. The contraindication applies only to IV verapamil and adenosine.
D) IV metoprolol is contraindicated. AV nodal blockers (including beta-blockers, verapamil, diltiazem, digoxin, and adenosine) in pre-excited AF slow conduction through the AV node, shifting more conduction through the accessory pathway. Accessory pathways have shorter refractory periods and can conduct at rates exceeding 300 bpm, potentially degenerating into ventricular fibrillation. Correct management is electrical cardioversion if hemodynamically unstable, or IV procainamide or IV ibutilide to block accessory pathway conduction directly if stable.
E) IV metoprolol is contraindicated only if the accessory pathway is left-sided. Right-sided pathways are remote from the AV node and beta-blockers can be given safely.

ANSWER: D

Rationale:

Pre-excited AF (WPW with AF) is one of the most critical contraindications in arrhythmia pharmacology. In this condition, AF impulses can conduct to the ventricles through both the AV node and the accessory pathway. The AV node limits conduction rate through its refractory period. AV nodal blocking agents (beta-blockers, verapamil, diltiazem, digoxin, and adenosine) slow or block AV nodal conduction, diverting more impulses through the accessory pathway. Accessory pathways can have refractory periods as short as 200 to 250 ms, allowing ventricular rates exceeding 300 bpm, which can degenerate into ventricular fibrillation. This applies to all AV nodal blockers without exception. Correct management for hemodynamically unstable pre-excited AF is immediate direct current cardioversion. For the stable patient, IV procainamide (which slows accessory pathway conduction) or IV ibutilide are appropriate pharmacologic options. The location of the accessory pathway (left-sided vs right-sided) is irrelevant to this contraindication.

11. A 66-year-old woman with HFrEF (EF 28%, NYHA Class III) is being uptitrated on her beta-blocker. She was started on metoprolol tartrate 25 mg twice daily 4 months ago by her internist and is currently on metoprolol tartrate 50 mg twice daily. Her cardiologist notes she is stable and euvolemic and asks whether her current regimen is acceptable for long-term HFrEF management. What is the problem with the current approach and what should be done?

A) Metoprolol tartrate 50 mg twice daily is too low a dose. It should be increased to 100 mg twice daily to match the doses used in MERIT-HF.
B) Metoprolol tartrate is acceptable but the total daily dose of 100 mg is not yet at the target dose of 200 mg daily. Continue uptitration of the tartrate formulation.
C) Metoprolol tartrate does not have proven mortality benefit in HFrEF. The MERIT-HF trial used metoprolol succinate CR/XL (controlled-release formulation), not tartrate. The patient should be transitioned to metoprolol succinate with uptitration toward the target dose of 200 mg daily used in MERIT-HF, recognizing that the maximum tolerated dose, not a fixed target, is the clinical goal.
D) The tartrate formulation is equivalent to the succinate formulation when given twice daily, as this approximates the sustained-release profile. No change is needed.
E) Switch from metoprolol tartrate to carvedilol. Carvedilol's additional alpha1-blocking property provides superior neurohormonal suppression in NYHA Class III HFrEF compared to any metoprolol formulation.

ANSWER: C

Rationale:

The distinction between metoprolol tartrate and metoprolol succinate is clinically critical in HFrEF. MERIT-HF used metoprolol succinate CR/XL, a controlled-release formulation providing sustained beta1-blockade over 24 hours. Metoprolol tartrate is an immediate-release formulation with a half-life of 3 to 7 hours, producing peak-and-trough plasma levels that do not replicate the pharmacokinetic profile studied in MERIT-HF. Metoprolol tartrate has not demonstrated mortality benefit in HFrEF in any randomized controlled trial and should not be used for this indication. The standard of care is to use one of the three proven agents (carvedilol, metoprolol succinate, or bisoprolol) at the maximum tolerated dose. The MERIT-HF target dose was 200 mg daily of metoprolol succinate, but clinical practice emphasizes titration to the maximum tolerated dose rather than a rigid target. This patient should be transitioned from tartrate to succinate and uptitrated accordingly. The formulation difference is not a matter of equivalent dosing convenience.